Ignite Creation Date:
2024-05-06 @ 12:37 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03801798
Status:
UNKNOWN
Last Update Posted:
2019-12-13
First Post:
2019-01-08
Brief Title:
A Study of GC1102Recombinant Hepatitis B Immunoglobulin in Chronic Hepatitis B Patients
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Double-blind Randomized Placebo Controlled Parallel-group Phase 2a Study to Evaluate the Efficacy and Safety of GC1102 in Combination With NucleostIde Analogues NAs in Patients With Chronic Hepatitis B
Status:
UNKNOWN
Status Verified Date:
2019-12
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of GC1102 in combination of Nucleotide analogues NAs in patients with chronic hepatitis B
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None